1-6 of 6
Alana Christie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans

Available to Purchase
Yuanqing Ma, Allison Joyce, Olivia Brandenburg, Faeze Saatchi, Christina Stevens, Vanina Toffessi Tcheuyap, Alana Christie, Quyen N. Do, Oluwatomilade Fatunde, Alyssa Macchiaroli, So C. Wong, Layton Woolford, Qurratulain Yousuf, Jeffrey Miyata, Deyssy Carrillo, Oreoluwa Onabolu, Tiffani McKenzie, Akhilesh Mishra, Tanner Hardy, Wei He, Daniel Li, Alexander Ivanishev, Qing Zhang, Ivan Pedrosa, Payal Kapur, Thomas Schluep, Steven B. Kanner, James Hamilton, James Brugarolas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5405–5418.
https://doi.org/10.1158/1078-0432.CCR-22-0963
Published: 15 December 2022
View article titled, HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Open the PDF for HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans in another window
Includes: Supplementary data
Journal Articles

ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma

Available to Purchase
Aditi Mulgaonkar, Roy Elias, Layton Woolford, Bing Guan, Kien Nham, Payal Kapur, Alana Christie, Vanina T. Tcheuyap, Nirmish Singla, I. Alex Bowman, Christina Stevens, Guiyang Hao, James Brugarolas, Xiankai Sun
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4907–4916.
https://doi.org/10.1158/1078-0432.CCR-22-1547
Published: 14 November 2022
View article titled, ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma
Open the PDF for ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma

Available to Purchase
Raquibul Hannan, Osama Mohamad, Alberto Diaz de Leon, Subrata Manna, Laurentiu M. Pop, Ze Zhang, Samantha Mannala, Alana Christie, Scott Christley, Nancy Monson, Dan Ishihara, Eric J. Hsu, Chul Ahn, Payal Kapur, Mingyi Chen, Yull Arriaga, Kevin Courtney, Brandi Cantarel, Edward K. Wakeland, Yang-Xin Fu, Ivan Pedrosa, Lindsay Cowell, Tao Wang, Vitaly Margulis, Hak Choy, Robert D. Timmerman, James Brugarolas
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6716–6725.
https://doi.org/10.1158/1078-0432.CCR-21-2083
Published: 15 December 2021
View article titled, Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma
Open the PDF for Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform

Available to Purchase
Durga Udayakumar, Ze Zhang, Yin Xi, Durgesh K. Dwivedi, Michael Fulkerson, Sydney Haldeman, Tiffani McKenzie, Qurratulain Yousuf, Allison Joyce, Asghar Hajibeigi, Hollis Notgrass, Alberto Diaz de Leon, Qing Yuan, Matthew A. Lewis, Ananth J. Madhuranthakam, Robert C. Sibley, Roy Elias, Junyu Guo, Alana Christie, Renée M. McKay, Jeffrey A. Cadeddu, Aditya Bagrodia, Vitaly Margulis, James Brugarolas, Tao Wang, Payal Kapur, Ivan Pedrosa
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4794–4806.
https://doi.org/10.1158/1078-0432.CCR-21-0706
Published: 01 September 2021
View article titled, Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Open the PDF for Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform in another window
Includes: Supplementary data
Journal Articles

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Available to Purchase
Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon, Alana Christie, Zhiqun Xie, Layton Woolford, Nirmish Singla, Allison Joyce, Haley Hill, Ananth J. Madhuranthakam, Qing Yuan, Yin Xi, Yue Zhang, Jenny Chang, Oluwatomilade Fatunde, Yull Arriaga, Arthur E. Frankel, Sanjeeva Kalva, Song Zhang, Tiffani McKenzie, Oscar Reig Torras, Robert A. Figlin, Brian I. Rini, Renée M. McKay, Payal Kapur, Tao Wang, Ivan Pedrosa, James Brugarolas
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 793–803.
https://doi.org/10.1158/1078-0432.CCR-19-1459
Published: 14 February 2020
View article titled, HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Open the PDF for HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract IA10: Renal cancer tumorgrafts: A validated model to evaluate novel targeted therapies

Free
Andrea Pavia-Jimenez, Wenfang Chen, Haley Hill, Alana Christie, Qurratulain Yousuf, Noelle Williams, Xian-Jin Xie, Payal Kapur, James Brugarolas
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): IA10.
https://doi.org/10.1158/1557-3265.PDX16-IA10
Published: 15 August 2016
View article titled, Abstract IA10: Renal cancer tumorgrafts: A validated model to evaluate novel targeted therapies